Conclusions: Apart from confirming well-known MLL-r BCP-ALL glycoprotein markers, our integrated multi-omics workflow discovered previously unidentified diagnostic/therapeutic protein targets. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.